The Pharmaceutical Benefits Advisory Committee (PBAC) has given positive recommendations for PBS listing for more hepatitis C direct-acting antiviral drugs.

The drugs recommended at the PBAC's November meeting include Sofosbuvir and Velpatasvir (Epclusa) for genotypes 1 to 6 and Paritaprevir, Ritonavir, Ombitasvir (Viekirax) for genotype 4.

Fixed dose, once a day Sofosbuvir/Velpatasvir is recommended for treating all genotypes.

It has also been shown to work for people with decompensated cirrhosis, when used together with ribavirin.

Both these drugs are expected to be listed with the Pharmaceutical Benefits Scheme (PBS) by April next year.

Grazoprevir and Elbasvir (with or without Ribavirin), which was approved at the previous PBAC meeting is expected to be listed with the PBS from 1 January 2017.